Expression of NADPH oxidase and production of reactive oxygen species in aorta in an active immunization mouse model with AT1-EC2 peptide

Abstract

The antibody against AT1-EC2 plays a role in some kinds of inflammatory vascular diseases including malignant hypertension, preeclampsia, and renal-allograft rejection, but the detailed mechanisms remain unclear. In order to investigate the changes of NADPH oxidase and reactive oxygen species in the aorta in a mouse model which can produce AT1-EC2 antibody by active immunization with AT1-EC2 peptide, 15 mice were divided into three groups: control group, AT1-EC2-immunized group, and AT1-EC2-immunized and valsartan-treated group. In AT1-EC2-immunized group and AT1-EC2-immunized and valsartan-treated group, the mice were immunized by 50 μg peptide subcutaneously at multiple points for 4 times: 0, 5, 10, and 15 days after the experiment. In AT1-EC2-immunized and valsartan-treated group, valsartan was given at a dose of 100 mg/kg every day for 20 days. After the experiment, the mice were sacrificed under anesthesia and the aortas were obtained and frozen in liquid nitrogen for the preparation of frozen section slides and other experiments. The titer of AT1-EC2 was assayed by using ELISA. The level of NOX1 mRNA in the aorta was determined by using RT-PCR. The expression of NOX1 was detected by using Western blotting. Confocal scanning microscopy was used to assay the α-actin and NOX1 expression in the aortic tissue. The O₂∸ production was detected in situ after DHE staining. The mice produced high level antibody against AT1-EC2 in AT1-EC2-immunized group and AT1-EC2-immunized and valsartan-treated group, and the level of NOX1 mRNA in the aortic tissues was 1.6±0.4 times higher and the NOX1 protein expression was higher in AT1-EC2-immunized group than in control group. There were no significant differences in the level of NOX1 mRNA and protein expression between control group and AT1-EC2-immunized and valsartan-treated group. The expression and co-localization of α-actin and NOX1 in AT1-EC2-immunized group increased significantly as compared with those in control group, and the O₂∸ production increased about 2.7 times as compared with control group. There were no significant differences between control group and AT1-EC2-immunized and valsartan-treated group. It is concluded that active immunization with AT1-EC2 can activate NOX1-ROS, and increase vascular inflammation, which can be inhibited by AT1 receptor blocker valsartan. This may partially explain the mechanism of the pathogenesis of inflammatory vascular diseases related to antibody against AT1-EC2.

Keywords

AT1-EC2 peptide / NADPH oxidase / reactive oxygen species / vascular inflammation

References

[1] WallukatG., HomuthV., FischerT., et al.. Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor. J Clin Invest, 1999, 103(7): 945-952

[2] FuM.L., HerlitzH., SchulzeW., et al.. Autoantibodies against the angiotensin receptor (AT1) in patients with hypertension. J Hypertens, 2000, 18(7): 945-953

[3] LiaoY.H., WeiY.M., WangM., et al.. Autoantibodies against AT1-receptor and alpha1-adrenergic receptor in patients with hypertension. Hypertens Res, 2002, 25(4): 641-646

[4] LuoY.S., LiaoY.H., WangM., et al.. Experimental study on AT1 receptor-peptide-induced myocardial immune damage in rats. J Tongji Med Univ Med Sci, 2001, 21(3): 198-201

[5] DragunD., MüllerD.N., BräsenJ.H., et al.. Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med, 2005, 352(6): 558-569

[6] DechendR., MüllerD.N., WallukatG., et al.. Activating auto-antibodies against the AT1 receptor in preeclampsia. Autoimmun Rev, 2005, 4(1): 61-65

[7] LiP.L., ZhangY., YiF.. Lipid raft redox signaling platforms in endothelial dysfunction. Antioxid Redox Signal, 2007, 9(9): 1457-1470

[8] BedardK., KrauseK.H.. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev, 2007, 87(1): 245-313

[9] AgoT., KurodaJ., KamouchiM., et al.. Pathophysiological roles of NADPH oxidase/nox family proteins in the vascular system. Circ J, 2011, 75(8): 1791-1800

[10] WangB., LiaoY.H., ZhouZ., et al.. Arterial structure changes in rats immunized by AT1-receptor peptide. Heart Vessels, 2005, 20(4): 153-158

[11] DikalovaA., ClempusR., LassègueB., et al.. Nox1 overexpression potentiates angiotensin II-induced hypertension and vascular smooth muscle hypertrophy in transgenic mice. Circulation, 2005, 112(17): 2668-2676

[12] SorescuD., WeissD., LassègueB., et al.. Superoxide production and expression of nox family proteins in human atherosclerosis. Circulation, 2002, 105(12): 1429-1435

[13] JankovR.P., KantoresC., PanJ., et al.. Contribution of xanthine oxidase-derived superoxide to chronic hypoxic pulmonary hypertension in neonatal rats. Am J Physiol Lung Cell Mol Physiol, 2008, 294(2): L233-245

[14] ZhuF., SunY.X., LiaoY.H., et al.. Agonistic AT(1) receptor autoantibody increases in serum of patients with refractory hypertension and improves Ca(2+) mobilization in cultured rat vascular smooth muscle cells. Cell Mol Immunol, 2008, 5(3): 209-217

[15] DechendR., HomuthV., WallukatG., et al.. AT(1) receptor agonistic antibodies from preeclamptic patients cause vascular cells to express tissue factor. Circulation, 2000, 101(20): 2382-2387

[16] DechendR., ViedtC., MüllerD.N., et al.. AT1 receptor agonistic antibodies from preeclamptic patients stimulate NADPH oxidase. Circulation, 2003, 107(12): 1632-1639

[17] DworakowskiR., Alom-RuizS.P., ShahA.M.. NADPH oxidase-derived reactive oxygen species in the regulation of endothelial phenotype. Pharmacol Rep, 2008, 60(1): 21-28

[18] GarridoA.M., GriendlingK.K.. NADPH oxidases and angiotensin II receptor signaling. Mol Cell Endocrinol, 2009, 302(2): 148-158